Posts Tagged ‘GLP-1 agonists’

It’s true. We have been getting some pretty good news about GLP-1s lately. In persons with prediabetes and obesity, tirzepatide was 94% effective at preventing the development of diabetes. In the SELECT study, semaglutide for obesity might have cut COVID fatalities by a third. So a little exuberance about the potential of GLP-1 medicines is […]

Novo Nordisk is creeping up on an indication for semaglutide in people with obesity and heart failure. Today in Lancet, we have another piece of the puzzle to suggest this drug might help. In a prespecified analysis from the SELECT study, researchers found that semaglutide reduced heart attacks, strokes, deaths, and problems with heart failure […]

Semaglutide – under the banner of Ozempic – has set a revolution of obesity medicines in motion. Suddenly, all of the huffing and puffing about “treating obesity seriously” and “obesity as a disease” is moot. Facts on the ground are persuading people to re-orient their thinking about obesity faster than essays and advocacy campaigns ever […]

A sea change in what people want to buy. This is what food companies that depend on making money from chips and other snacks are seeing. Some brush it off as consumers becoming more “value-conscious” in the face of economic uncertainty. But others are getting to work on figuring out how to cope as they […]

Narratives are powerful. One of the early dominant narratives of the rising demand for Ozempic and related drugs was all about Hollywood, appearances, and privilege. But Bloomberg has a counter-narrative for us. The center of gravity for Ozempic demand is not Hollywood. It’s really Bowling Green, Kentucky. The food environment here is more Waffle House […]

On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]

When the subject of equitable access to GLP-1s arises, contrasting perspectives of what is equitable become apparent. Last week in the Annals of Internal Medicine, an analysis of prescription data for GLP-1 agonists made two facts about their use very clear. First, their use for obesity is growing much faster than the use for type […]

The rousing success of GLP-1 medicines for obesity and overweight evokes a wide range of feelings. At the National Academy of Sciences this week we heard lamentations from a scholar in exercise physiology. To him, these highly effective treatments are a distraction from the importance of focusing in healthy eating and active living. We hear […]

“If we were just to get a fraction [of potential members] to engage in the way that we do things differently with GLP-1s – it’s an insane opportunity for the company.” These words come from the Life Time chain of fitness clubs about the “Miora” wellness clinics they are now putting inside their facilities. It […]

What should we take away from yet another suggestion that semaglutide might cut the risk of dementia? An Unexpected Finding This latest hint was a surprise. It comes from research that aimed to measure the risk of neurological and psychiatric problems associated with taking semaglutide for type 2 diabetes. Riccardo De Giorgi and colleagues were […]